Evidence map›Paper›PMID 36199883›Full record

ArticleRSC advances2022

Palladium-catalyzed C-H olefination of uridine, deoxyuridine, uridine monophosphate and uridine analogues.

Qin Zhao, Ruoqian Xie, Yuxiao Zeng, Wanlu Li, Guolan Xiao, Yangyan Li, Gang Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qin ZhaoShanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University Shanghai 200240 People's Republic of China yangany_li@sjtu.edu.cn gchen2018@sjtu.edu.cn.
Ruoqian XieShanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University Shanghai 200240 People's Republic of China yangany_li@sjtu.edu.cn gchen2018@sjtu.edu.cn.
Yuxiao ZengShanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University Shanghai 200240 People's Republic of China yangany_li@sjtu.edu.cn gchen2018@sjtu.edu.cn.ORCID https://orcid.org/0000-0002-8288-7025
Wanlu LiSchool of Chemistry and Chemical Engineering, Southeast University Nanjing 211189 People's Republic of China.
Guolan XiaoShanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University Shanghai 200240 People's Republic of China yangany_li@sjtu.edu.cn gchen2018@sjtu.edu.cn.
Yangyan LiShanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University Shanghai 200240 People's Republic of China yangany_li@sjtu.edu.cn gchen2018@sjtu.edu.cn.
Gang ChenShanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University Shanghai 200240 People's Republic of China yangany_li@sjtu.edu.cn gchen2018@sjtu.edu.cn.ORCID https://orcid.org/0000-0003-1683-7676

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The palladium-catalyzed oxidative C-H olefinations of uridine, deoxyuridine, uridine monophosphate and uridine analogues are reported herein. This protocol provides an efficient, atom-economic and environmentally friendly approach to the synthesis of biologically important C5-alkene modified uracil/uridine-containing derivatives and pharmaceutical candidates.

Identifiers

PMID36199883
PMCPMC9434382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.